

Remarks

The sequence listing has been amended to correct an alleged error in listing sequences as "Artificial" rather than as "Artificial Sequence." More particularly, the Examiner contends that the use of the term "Artificial" in an entry under code <213> in a sequence listing is incomplete and fails to comply with 37 C.F.R. § 1.823(b), and that the valid entry is "Artificial Sequence." *See* Paper No. 28, Raw Sequence Listing Error Report.

In response, Applicants respectfully point out that the sequence listing was generated by the PatentIn 3.0 software provided by the Patent Office. Applicants note that the PatentIn software inserted the "Artificial" text, and further that the Checker software provided by the Patent Office did not note any errors in the sequence listing. However, Applicants submit herewith a Third Substitute Sequence Listing in which all occurrences of the term "Artificial" in code <213> have been replaced with the term "Artificial Sequence."

Conclusion


Entry and consideration of the above amendment and remarks is respectfully solicited. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicant would expedite the examination of this application.

Applicants believe that there are no fees due in connection with the filing of this paper. However, should a fee be due, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an

extension is requested and the appropriate fee should also be charged to our Deposit Account.

Respectfully submitted,

Dated: May 8, 2001



Mark J. Hyman (Reg. No. 46,789)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (240) 314-1224

Enclosures